A 35-year-old woman with a 10-year history of schizophrenia, currently on olanzapine 15 mg daily, presents with persistent auditory hallucinations and delusions despite adequate dosing for 8 weeks. She is adherent to medication (confirmed by pill count and plasma levels). Her last antipsychotic change was 3 years ago. What is the most appropriate next step in management?

Explanation

## Management of Treatment-Resistant Schizophrenia (TRS) **Key Point:** Treatment resistance is defined as failure to achieve adequate response to ≥2 antipsychotics at therapeutic doses for ≥4–6 weeks each. This patient meets criteria: persistent symptoms despite adequate olanzapine dosing (15 mg is therapeutic) for 8 weeks with documented adherence. ### Definition & Diagnosis of TRS **High-Yield:** TRS is present when: - Inadequate response to ≥2 sequential antipsychotics (first-generation or second-generation) - Each trial ≥4–6 weeks at therapeutic dose - Documented adherence - Positive symptoms persist (as in this case) ### Why Clozapine is the Gold Standard for TRS | Feature | Clozapine | |---|---| | **Efficacy in TRS** | 30–50% response rate in TRS vs. 5–10% with other antipsychotics | | **Mechanism** | Unique D1/D2 antagonism + serotonergic activity; may work via different pathway | | **Evidence level** | Grade A; multiple RCTs support superiority in TRS | | **Timing** | Should be offered early in TRS course | **Clinical Pearl:** Clozapine is underutilized due to fear of agranulocytosis, but with modern monitoring (baseline CBC, then weekly × 6 months, then biweekly × 6 months, then monthly), the risk is <1%. The benefit in TRS far outweighs this risk. **Mnemonic: CLOZAPINE FIRST** — **C**lear indication (TRS), **L**ow risk if monitored, **O**ther drugs failed, **Z**ero alternatives as effective, **A**granulocytosis monitored, **P**sychotic symptoms resolve in 30–50%, **I**ncrease quality of life, **N**eed baseline labs, **E**arly intervention improves outcomes. ### Pre-Clozapine Workup 1. **Baseline investigations:** CBC (absolute neutrophil count >1500), LFTs, lipids, glucose, prolactin, weight, BMI, EKG (QTc) 2. **Washout:** Taper olanzapine over 1–2 weeks to avoid withdrawal; clozapine can be started during taper 3. **Informed consent:** Discuss agranulocytosis risk, metabolic effects, seizure risk, myocarditis (rare but serious) 4. **Monitoring plan:** Weekly CBC × 6 months, then biweekly × 6 months, then monthly ### Why Other Options Are Suboptimal ```mermaid flowchart TD A[Persistent psychotic symptoms<br/>on adequate antipsychotic]:::outcome --> B{Adherence confirmed?}:::decision B -->|No| C[Address adherence<br/>LAI, psychoeducation]:::action B -->|Yes| D{Adequate dose &<br/>duration?}:::decision D -->|No| E[Optimize dose/duration]:::action D -->|Yes| F{Treatment-resistant<br/>schizophrenia?}:::outcome F -->|Yes| G[Clozapine + baseline labs]:::action F -->|No| H[Consider augmentation<br/>or switch]:::action G --> I[Monitor CBC weekly]:::action ``` **Why increasing olanzapine (Option A):** Already at therapeutic dose for 8 weeks; further increase unlikely to help and increases metabolic risk. Dose escalation beyond 15–20 mg shows diminishing returns. **Why antidepressant alone (Option C):** No evidence of mood disorder driving psychotic symptoms. Antidepressants do not address core psychosis in TRS and may worsen symptoms if used as monotherapy. **Why CBTp without medication change (Option D):** CBTp is valuable adjunct but cannot replace pharmacotherapy in TRS. Psychotherapy alone is insufficient when antipsychotics have failed. [cite:Kaplan & Sadock 11e Ch 295; Meltzer et al. Am J Psychiatry 2003]